RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
I certainly hope that you are right Note as I do not consider 3rd line patients with a compromised immune system the same patient population that was in the mbc 213 trial. As for the 55k patients, whether it will be easy to enrol or not depends upon how well we are promoted as it is still a trial and there might be a lot of companies trying for the same patients. Market has great potential but that is only if we were to capture the entire market of course (which we are hoping for panc for example) but then again that is only the potential and it would be most likely split up against competing entitities. ONC has never run a quick trial so IMO only we will be lucky if the trial even starts in 2025 as there is a lot to be approved and get into place and then enrol the patients and then wait for the first efficacy readout which is most likely sometime in 2026 if we are lucky which at this time is when the fda would look at the possibility of AA but then again only with results that warrant it. Guess we shall see but will be interesting to see how much the soon to be announced mbc os results play into things. That is the big question.